Jump to content

Yihai Cao

Add links
From Wikipedia, the free encyclopedia
The native form of this personal name is Cao Yihai. This article uses Western name order when mentioning individuals.
Yihai Cao
曹义海
Born (1959-10-29) October 29, 1959 (age 65)
Jinan, Shandong, China
CitizenshipSweden
Known forAngiogenesis research
SpouseAnna-Zarah
Children2
Scientific career
FieldsCancer, Metabolic diseases, Cardiovascular diseases
InstitutionsKarolinska Institute, Stockholm, Sweden
Thesis Expression of acidic fibroblast growth factor in vitro and in the brain  (1993)
Doctoral advisorRalf Pettersson
Other academic advisorsJudah Folkman
Websiteki.se/en/people/yihcao

Yihai Cao, M.D., hM. D.,[1] Ph.D., (Chinese: 曹义海; born October 29, 1959) is a Chinese-born Swedish scientist and a professor at the Karolinska Institute, Sweden.[2] He is also an honorary professor or guest professor in Copenhagen University, Denmark; Linköping University, Sweden; Leicester University, UK; Shinshu University, Japan; Shandong University, China; and Peking University, China. He is an internationally recognized and cited researcher in cancer, obesity, diabetes, cardiovascular disease, and eye disease research. His publications have been cited more than 35,000 times and his h-index is 92.[3] Cao received the Fernström research prize,[4] the Karolinska distinguished professor award,[5] and the Axel Hirsch Prize in medicine.[6] Cao received an ERC-advanced research grant award,[7] and a Novo Nordisk-advanced grant award.[8] From 2018, Cao was elected to Academia Europaea, the European Academy of Sciences and Arts, the Chinese Academy of Engineering, the National Academy of Inventors, and The World Academy of Sciences. His research findings received broad public attentions including New York Times, Reuters and Swedish National TV broad casting.[9][10][11]

Contributions to medicine

[edit]

Cao participated in the discovery of angiostatin, an endogenous angiogenesis inhibitor, in Judah Folkman ́s Laboratory.[12] He discovered several angiostatic proteins for potential treatment of cancer.[13][14][15] Cao's laboratory discovered catechins in green tea as oral angiogenesis inhibitors.[16] They also discovered several lymphangiogenic factors that potentially contribute to cancer metastasis.[17][18] Cao proposed a new concept of off-tumor targets of antiangiogenic drugs as potential clinical benefits by improving systemic disease in cancer patients.[19][20] Together with Henrich Cheng and Lars Olson, Cao for the first time shows that spinal cord can be regenerated by FGF-1.[21] Cao's laboratory was one of the first proposing the concept of combination therapy comprising angiogenic and arteriogenic factors for treatment of ischemic muscle disease.[22] They were one of the first who proposed targeting adipose angiogenesis for treatment of obesity and metabolic diseases.[23][24][25]

Founder of companies

[edit]

Cao founded Swenora in 2001,[26] which develops new therapeutics for treatment of spinal cord injury. In 2005, he founded Clanotech,[27] which develops novel antiangiogenic drugs for treatment of ocular disease and fibrosis disease.

References

[edit]
  1. ^ Nygaard, Johannes (2016-06-09). "Honorary Doctors". healthsciences.ku.dk. Retrieved 2017-02-23.
  2. ^ "Yihai Cao". ki.se. Retrieved 2017-02-22.
  3. ^ "Yihai Cao - Google Scholar Citations". scholar.google.se. Retrieved 2017-02-24.
  4. ^ University, Faculty of Medicine, Lund. "Pristagare | Medicinska fakulteten, Lunds universitet". www.med.lu.se (in Swedish). Retrieved 2017-02-24.{{cite web}}: CS1 maint: multiple names: authors list (link)
  5. ^ "Angiogenesis in Obesity & Diabetes | School of Medicine". medicine.dundee.ac.uk. Retrieved 2017-02-22.
  6. ^ "Axel Hirsch Prize for groundbreaking research on angiogenesis". ki.se. Retrieved 2017-02-22.
  7. ^ "European Commission : CORDIS : Projects & Results Service : New mechanisms of angiogenesis modulators in switching between white and brown adipose tissues". cordis.europa.eu. Retrieved 2017-02-22.
  8. ^ "Novo Nordisk Foundation Advanced Grant | Novo Nordisk Fonden". novonordiskfonden.dk. Retrieved 2017-02-22.
  9. ^ Kolata, Gina (1996-07-26). "Doctors in Sweden Document That a Severed Spinal Cord Can RepairItself". The New York Times. ISSN 0362-4331. Retrieved 2017-02-24.
  10. ^ "Heart hospitalizations may spike days after snowstorms pass". Reuters. 2017-01-30. Retrieved 2017-02-24.
  11. ^ Nyheter, SVT. "Vill du bli smal och frisk? – Börja frysa!". svt.se (in Swedish). Retrieved 2017-02-24.
  12. ^ O'Reilly, M. S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R. A.; Moses, M.; Lane, W. S.; Cao, Y.; Sage, E. H. (1994-10-21). "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma". Cell. 79 (2): 315–328. doi:10.1016/0092-8674(94)90200-3. ISSN 0092-8674. PMID 7525077. S2CID 27799550.
  13. ^ Cao, Y.; Chen, A.; An, S. S.; Ji, R. W.; Davidson, D.; Llinás, M. (1997-09-05). "Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth". The Journal of Biological Chemistry. 272 (36): 22924–22928. doi:10.1074/jbc.272.36.22924. ISSN 0021-9258. PMID 9278456.
  14. ^ Cao, Y.; Chen, C.; Weatherbee, J. A.; Tsang, M.; Folkman, J. (1995-12-01). "gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice". The Journal of Experimental Medicine. 182 (6): 2069–2077. doi:10.1084/jem.182.6.2069. ISSN 0022-1007. PMC 2192268. PMID 7500052.
  15. ^ Cao, R.; Wu, H. L.; Veitonmäki, N.; Linden, P.; Farnebo, J.; Shi, G. Y.; Cao, Y. (1999-05-11). "Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis". Proceedings of the National Academy of Sciences of the United States of America. 96 (10): 5728–5733. Bibcode:1999PNAS...96.5728C. doi:10.1073/pnas.96.10.5728. ISSN 0027-8424. PMC 21928. PMID 10318952.
  16. ^ Cao, Y.; Cao, R. (1999-04-01). "Angiogenesis inhibited by drinking tea". Nature. 398 (6726): 381. Bibcode:1999Natur.398..381C. doi:10.1038/18793. ISSN 0028-0836. PMID 10201368. S2CID 4419971.
  17. ^ Cao, Renhai; Björndahl, Meit A.; Religa, Piotr; Clasper, Steve; Garvin, Stina; Galter, Dagmar; Meister, Björn; Ikomi, Fumitaka; Tritsaris, Katerina (2004-10-01). "PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis". Cancer Cell. 6 (4): 333–345. doi:10.1016/j.ccr.2004.08.034. ISSN 1535-6108. PMID 15488757.
  18. ^ Kubo, Hajime; Cao, Renhai; Brakenhielm, Ebba; Mäkinen, Taija; Cao, Yihai; Alitalo, Kari (2002-06-25). "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea". Proceedings of the National Academy of Sciences of the United States of America. 99 (13): 8868–8873. Bibcode:2002PNAS...99.8868K. doi:10.1073/pnas.062040199. ISSN 0027-8424. PMC 124390. PMID 12070340.
  19. ^ Xue, Yuan; Religa, Piotr; Cao, Renhai; Hansen, Anker Jon; Lucchini, Franco; Jones, Bernt; Wu, Yan; Zhu, Zhenping; Pytowski, Bronislaw (2008-11-25). "Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome". Proceedings of the National Academy of Sciences of the United States of America. 105 (47): 18513–18518. Bibcode:2008PNAS..10518513X. doi:10.1073/pnas.0807967105. ISSN 1091-6490. PMC 2587583. PMID 19017793.
  20. ^ Cao, Yihai (2010-10-01). "Off-tumor target--beneficial site for antiangiogenic cancer therapy?". Nature Reviews. Clinical Oncology. 7 (10): 604–608. doi:10.1038/nrclinonc.2010.118. ISSN 1759-4782. PMID 20683436. S2CID 39237247.
  21. ^ Cheng, H.; Cao, Y.; Olson, L. (1996-07-26). "Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function". Science. 273 (5274): 510–513. Bibcode:1996Sci...273..510C. doi:10.1126/science.273.5274.510. ISSN 0036-8075. PMID 8662542. S2CID 36400308.
  22. ^ Cao, Renhai; Bråkenhielm, Ebba; Pawliuk, Robert; Wariaro, David; Post, Mark J.; Wahlberg, Eric; Leboulch, Philippe; Cao, Yihai (2003-05-01). "Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2". Nature Medicine. 9 (5): 604–613. doi:10.1038/nm848. ISSN 1078-8956. PMID 12669032. S2CID 9510523.
  23. ^ Bråkenhielm, Ebba; Cao, Renhai; Gao, Bihu; Angelin, Bo; Cannon, Barbara; Parini, Paolo; Cao, Yihai (2004-06-25). "Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice". Circulation Research. 94 (12): 1579–1588. doi:10.1161/01.RES.0000132745.76882.70. ISSN 1524-4571. PMID 15155527.
  24. ^ Cao, Yihai (2007-09-01). "Angiogenesis modulates adipogenesis and obesity". The Journal of Clinical Investigation. 117 (9): 2362–2368. doi:10.1172/JCI32239. ISSN 0021-9738. PMC 1963348. PMID 17786229.
  25. ^ Cao, Yihai (2010-02-01). "Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases". Nature Reviews. Drug Discovery. 9 (2): 107–115. doi:10.1038/nrd3055. ISSN 1474-1784. PMID 20118961. S2CID 12594149.
  26. ^ "Swenora Biotech AB Lagmansvägen, Lidingö - hitta.se". hitta.se (in Swedish). Retrieved 2017-02-22.
  27. ^ "Clanotech AB". www.clanotech.se. Retrieved 2017-02-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Yihai_Cao&oldid=1243066176"